PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17440073-6	2007	Consistently, endogenous SAG is induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) with an induction time course following the c-Jun induction in both mouse epidermal JB6-Cl.41 and human 293 cells.	sagopilone	25-28	jun proto-oncogene	Mus musculus	130-135	
17440073-7	2007	TPA-mediated SAG induction was significantly reduced in JB6-Cl.41 cells overexpressing a dominant-negative c-Jun, indicating a requirement of c-Jun/AP-1.	sagopilone	13-16	jun proto-oncogene	Mus musculus	107-112	
17440073-7	2007	TPA-mediated SAG induction was significantly reduced in JB6-Cl.41 cells overexpressing a dominant-negative c-Jun, indicating a requirement of c-Jun/AP-1.	sagopilone	13-16	jun proto-oncogene	Mus musculus	142-147	
17440073-7	2007	TPA-mediated SAG induction was significantly reduced in JB6-Cl.41 cells overexpressing a dominant-negative c-Jun, indicating a requirement of c-Jun/AP-1.	sagopilone	13-16	jun proto-oncogene	Mus musculus	148-152	
17440073-8	2007	On the other hand, SAG seemed to modulate the c-Jun levels.	sagopilone	19-22	jun proto-oncogene	Mus musculus	46-51	
18258608-6	2008	The net outcome of SAG-mediated inhibition of c-Jun/AP-1 (pro-tumor promotion) and of p27 (antiproliferation) increased skin hyperplasia, with no apparent effect on apoptosis, as evidenced by increased skin thickness, and increased rate of DNA synthesis, but hardly any apoptosis.	sagopilone	19-22	jun proto-oncogene	Mus musculus	46-51	
18258608-6	2008	The net outcome of SAG-mediated inhibition of c-Jun/AP-1 (pro-tumor promotion) and of p27 (antiproliferation) increased skin hyperplasia, with no apparent effect on apoptosis, as evidenced by increased skin thickness, and increased rate of DNA synthesis, but hardly any apoptosis.	sagopilone	19-22	jun proto-oncogene	Mus musculus	52-56	
17846172-2	2007	We report that, when expressed in mouse epidermis driven by the K14 promoter, SAG inhibited TPA-induced c-Jun levels and activator protein-1 (AP-1) activity in both in vitro primary culture, in vivo transgenic mice, and an AP-1- luciferase reporter mouse model.	sagopilone	78-81	jun proto-oncogene	Mus musculus	104-109	
17846172-2	2007	We report that, when expressed in mouse epidermis driven by the K14 promoter, SAG inhibited TPA-induced c-Jun levels and activator protein-1 (AP-1) activity in both in vitro primary culture, in vivo transgenic mice, and an AP-1- luciferase reporter mouse model.	sagopilone	78-81	jun proto-oncogene	Mus musculus	121-140	
17846172-2	2007	We report that, when expressed in mouse epidermis driven by the K14 promoter, SAG inhibited TPA-induced c-Jun levels and activator protein-1 (AP-1) activity in both in vitro primary culture, in vivo transgenic mice, and an AP-1- luciferase reporter mouse model.	sagopilone	78-81	jun proto-oncogene	Mus musculus	142-146	
17846172-2	2007	We report that, when expressed in mouse epidermis driven by the K14 promoter, SAG inhibited TPA-induced c-Jun levels and activator protein-1 (AP-1) activity in both in vitro primary culture, in vivo transgenic mice, and an AP-1- luciferase reporter mouse model.	sagopilone	78-81	jun proto-oncogene	Mus musculus	223-227	
17846172-6	2007	Thus, SAG, in a manner depending on the availability of F-box proteins, demonstrated early-stage suppression of tumor formation by promoting c-Jun degradation, thereby inhibiting AP-1, and later-stage enhancement of tumor growth, by promoting inhibitor of kappaBalpha degradation to activate NF-kappaB and inhibit apoptosis.	sagopilone	6-9	jun proto-oncogene	Mus musculus	141-146	
17846172-6	2007	Thus, SAG, in a manner depending on the availability of F-box proteins, demonstrated early-stage suppression of tumor formation by promoting c-Jun degradation, thereby inhibiting AP-1, and later-stage enhancement of tumor growth, by promoting inhibitor of kappaBalpha degradation to activate NF-kappaB and inhibit apoptosis.	sagopilone	6-9	jun proto-oncogene	Mus musculus	179-183